The US Preventive Services Task Force (USPSTF) has recommended screening of adults at increased risk for latent tuberculosis (TB) infection (LTBI). 1 This recommendation (B statement) is based on an evidence review 2 that found that available tests-in particular, the tuberculin skin test and interferon-γ release assays-were sufficiently accurate to identify persons with LTBI and that TB preventive treatment (TPT) regimens now recommended in the US 3 should provide moderate net benefit 1 to persons identified from screening. The USPSTF advised following the recommendations for testing in persons who have immunosuppression made by the American Thoracic Society and Centers for Disease Control and Prevention 2017 4 and recommendations for TPT made by the Centers for Disease Control and Prevention in 2020. 3 The USPSTF noted that this recommendation is for adults not included in other recommendations 3,4 for LTBI testing and treatment, such as persons living with HIV, persons about to receive a solid-organ transplantation or tumor necrosis factor-α inhibitors, or other groups at increased risk because of immune suppression. The task force also noted that this recommendation is not for contacts of persons with a recent diagnosis of active TB disease, who are generally investigated by public health services. Hence, these recommendations are focused on persons who are otherwise healthy but have increased likelihood (risk) of having TB infection. Although this includes some US-born persons, the vast majority of persons who will be affected by this recommendation are individuals who immigrated to the US from countries where TB incidence is much higher. On the basis of estimates of the prevalence of LTBI among persons in the US who were born outside the US, 5 this represents a very substantial increase from the number of persons now screened.Before starting screening, a reminder is needed. The USPSTF also recommends that to achieve the benefit of screening, it is important that persons who screen positive for LTBI receive follow-up and treatment 1 ; if TPT is not completed, then there will be no benefit of screening. Hence, a decision to implement screening for LTBI in any setting or for any population must include a commitment to ensure adequate follow-up of those with positive test results. 6 This includes medical and radiographic evaluation to exclude TB disease, offering TPT to all those who are eligible, and then education and counseling plus subsequent close follow-up of those who accept TPT, to ensure adherence as well as to detect and manage any adverse effects. Substantial time and resources are needed to ensure that care is well organized for all steps in the cascade to minimize losses, or a screening program will have far less benefit than expected. 6 Numerous studies have shown that there are substantial losses in the cascade of LTBI care, at the steps of initial identification of candidates for screening (testing), medical evaluation, and offering TPT, as well as acceptance and completion of TPT by individuals,...